15:35:05 EDT Sun 25 Oct 2020
Enter Symbol
or Name

Login ID:
Livewell Canada Inc
Symbol LVWL
Shares Issued 129,749,624
Close 2018-10-05 C$ 1.21
Recent Sedar Documents

Livewell to acquire supplement manufacturer Acenzia

2018-10-05 11:05 ET - News Release

Mr. David Rendimonti reports


Livewell Canada Inc. has signed a binding letter of intent (LOI) to acquire 100 per cent of Acenzia Inc., a leading developer and manufacturer of next-generation natural health products located strategically near the Canada-United States border near Windsor, Ont.


  • A global-patented research model for preclinical trials;
  • $2.9-million in revenue generated by Acenzia for the four-month period ended Aug. 31, 2018, and $5.6-million in revenue for the fiscal year ended April 30, 2018;
  • Health Canada-certified, NSF GMP-registered (good manufacturing practices) and NSF GMP for Sport-registered manufacturing facility.

The transaction is part of Livewell Canada's vision to become a world leader in health and wellness through quality outcomes and strategic partnerships. Livewell Canada is an innovative Canadian hemp and cannabis company focused on advanced research in cannabidiol and other cannabinoids, as well as developing and distributing prescription and consumer health products supported by data, discovery, science and technology.

Blending science and advanced manufacturing, Acenzia is an innovator in rapid product development, as well as personalized diagnostics and therapeutics specific to particular medical conditions. These capabilities will further Livewell Canada's leadership in health-related research in cannabis and hemp, and fast-track its product development at a lower cost than conventional product development.

As legalization and acceptance of cannabidiol accelerate at a rapid pace globally, the demand for cannabidiol products to improve health and wellness is exploding. Livewell Canada has conducted major research on cannabidiol, a white paper on cannabidiol from Industrial Hemp, and is investing in technologies for the extraction and isolation of cannabidiol and other cannabinoids for use in prescription and consumer health products. As previously announced, Livewell Canada has secured inventory of hemp biomass for its own products and to sell as isolate for delivery in 2019.

Strategically located 15 kilometres from the Canada-United States border in Tecumseh, Ont., Acenzia researches and manufactures next-generation natural health products, such as powders, sports drinks, functional foods, probiotics and other therapeutics, as well as individualized diagnostics. Acenzia's 36,000-square-foot facility includes 20 state-of-the-art, pharmaceutical-grade clean rooms. It is certified by Health Canada, has NSF certifications for GMP and GMP for Sport, is a U.S. Department of Agriculture-certified organic manufacturer and is a Food and Drug Administration-registered facility. The company has achieved several significant milestones, including:

  • A global-patented in vivo zebrafish research model for preclinical trials, allowing more rapid product development at a lower cost;
  • An easy-to-access diagnostic tool kit that enables consumers to measure product efficacy at an individual level;
  • A new patent-pending delivery technology (oral time-released pouch) for the sports nutrition market, in partnership with Pro-Dip -- the company is entering a 10-year exclusive manufacturing agreement for this technology and will receive 6 per cent of gross sales revenue;
  • Evidence-based nutritional supplement manufactured with batch-to-batch efficacy.

Of particular note is its global-patented animal research model using zebrafish modified to mimic the human body. The zebrafish models allow for faster, more economical and effective trials that maximize safety and efficacy. Importantly, the research model optimizes product development to meet functional outcomes. Acenzia is currently applying its global-patented zebrafish research model to oncology -- to predict metastasis and support therapeutic decisions -- and it holds much wider applications, including cannabinoids.

"The acquisition of Acenzia represents an opportunity for proprietary brand insight and product innovation," commented David Rendimonti, president of Livewell Canada. "Such next-generation therapeutics can be paired with easy-to-access diagnostics that enable evaluation of the product efficacy at an individual level. These innovative products fall into a category of their own."

In addition to Acenzia's research, product development and manufacturing expertise, Livewell Canada welcomes the addition of Acenzia's leadership to its team. Dr. Indrajit Sinha and Grant Bourdeau are the co-founders and co-presidents of Acenzia. "Indrajit is a very strong researcher and Grant is a very capable manufacturer, and, together, create a strong culture that aligns with Livewell," added Mr. Rendimonti.

Mr. Bourdeau said the transaction brings together, "Like-minded partners to realize the vision of improving the outcome of individuals' health optimization." Dr. Sinha added: "We are an innovative company with a big dream. To put the pieces together -- manufacturing and research to commercialize -- is difficult. To go the next level, you need a strategic partner who understands customers' needs, with knowledge of the market. Livewell brings us that."

Transaction summary:

  • Total purchase consideration is set at $20-million, with $2-million cash paid at closing and $18-million in common shares of Livewell Canada based on the 20-day weighted average immediately prior to the date of the definitive agreement.
  • Of the $18-million in common shares, $8-million will be held in escrow and will be released subject to achieving a profitability milestone for calendar 2019.
  • Acenzia's revenue for the four months ended Aug. 31, 2018, was $2.9-million. For the fiscal year ended April 30, 2018, its revenue was $5.6-million (unaudited).
  • A finder's fee of 0.5 per cent will be payable from the cash consideration at closing.

Livewell Canada's board has unanimously approved this arm's-length transaction, subject to due diligence, standard closing conditions and TSX Venture Exchange approval. No approval of shareholders from either Acenzia or Livewell Canada is required in connection with this transaction. This transaction is expected to close on or before Nov. 30, 2018.

About Livewell Canada Inc.

Livewell Canada is focused on improving health one person at a time, utilizing innovation supported by data, discovery, science and technology. The cannabis and hemp company is conducting advanced research on CBD and other cannabinoids, as well as developing and distributing prescription and consumer health and wellness products.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.